Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients
Previous Treated Metastatic Non-small Cell Lung Cancer
Conditions: official terms
Carcinoma, Non-Small-Cell Lung
Conditions: Keywords
Pemetrexed, Gefitinib, iressa, alimta
Study Type
Study Phase
Phase 2
Study Design
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Name: Gefitinib Type: Drug
Name: Pemetrexed Type: Drug
Overall Status
To compare the efficacy of gefitinib versus pemetrexed as second-line chemotherapy for patients with previous treated non-small cell lung cancer
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Cells pathologically diagnosed as histological or radical surgery or radiation therapy is not possible stage IIIB and stage IV non-small-cell lung cancer patients

- second line

- ECOG 0~2

- Patients with normal liver function and renal function

Exclusion Criteria:

- Patients with severe acute infection requiring antibiotic therapy

- Patients who have received treatment in other areas of cancer within 5 years

- During pregnancy and lactation patients
Gachon university Gil Medical Center
Incheon, Korea, Republic of
Status: Recruiting
Contact: HeeKyung Ahn, professor - +82-32-460-2625 -
Start Date
February 2008
Completion Date
December 2013
Gachon University Gil Medical Center
Gachon University Gil Medical Center
Record processing date processed this data on July 28, 2015 page